Ovapuldencel-T

Drug Profile

Ovapuldencel-T

Alternative Names: Ovarian cancer stem cell therapy - NeoStem Oncology

Latest Information Update: 03 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer NeoStem Oncology
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Ovarian cancer

Most Recent Events

  • 25 Apr 2016 NeoStem withdraws a phase II trial for Ovarian cancer in USA priro to enrolment (NCT02033616)
  • 15 Mar 2016 Biomarkers information updated
  • 11 Sep 2014 NeoStem Oncology licenses patents covering methods for use of apoptotic cells to deliver antigen to dendritic cells from Rockefeller University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top